| EMR |
Report |
Adjusted EPS |
BEAT |
pred ~$1.70 vs. cons $1.68 |
MEDIUM |
| EMR |
Report |
Underlying sales growth |
IN-LINE |
pred ~4.6% vs. cons 5.0% |
MEDIUM |
| EMR |
Report |
Underlying orders growth |
MISS |
pred ~3.8% vs. cons 5.0% |
MEDIUM |
| EMR |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$6.50 midpoint vs. cons $6.51 (FY2026) |
HIGH |
| EMR |
Guide |
FY2026 underlying sales growth |
UNCHANGED |
guide ~3.0% vs. cons 3.1% (FY2026) |
HIGH |
| EMR |
Guide |
FY2026 free cash flow |
UNCHANGED |
guide ~$3.55B midpoint vs. cons $3.55B (FY2026) |
MEDIUM |
| EMR |
Guide |
Implied FY2026 Q4 adjusted EPS |
LOWER |
guide ~$1.80 vs. cons $1.84 (FY2026 Q4) |
MEDIUM |
| EMR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.2% |
— |
MEDIUM |
| EMR |
Return |
5-day cumulative residual |
-3.4% (FOLLOW-THROUGH) |
A ~$1.70 EPS print versus $1.68 consensus is outweighed by ~3.8% orders versus 5.0% consensus and ~$1.80 implied Q4 EPS versus $1.84 consensus, creating modest out-period estimate cuts. |
MEDIUM |